两名老年男性在接受前列腺癌去势治疗时出现重症肌无力。
Two Elderly Men with Myasthenia Gravis during Androgen Deprivation Therapy for Prostate Cancer.
机构信息
Department of Neurology, Juntendo University, School of Medicine, Japan.
出版信息
Intern Med. 2023 Aug 15;62(16):2413-2414. doi: 10.2169/internalmedicine.0474-22. Epub 2023 Jan 12.
Abstract
Myasthenia gravis (MG) development is female-dominant in younger patients and male-dominant in older patients. The reason for the sex-ratio inversion in elderly MG patients remains unclear. One possible explanation is the decrease in androgen secretion that occurs with aging, as androgen has an immunosuppressive function. We experienced two elderly men who developed MG after initiating androgen deprivation therapy (ADT) for treatment of prostate cancer and whose symptoms were ameliorated after ADT cessation. Our cases indicate that MG in older male patients can be caused by an androgen effect.
摘要
重症肌无力（MG）在年轻患者中以女性为主，在老年患者中以男性为主。老年 MG 患者性别比例倒置的原因尚不清楚。一种可能的解释是随着年龄的增长，雄激素分泌减少，因为雄激素具有免疫抑制作用。我们遇到两名老年男性，他们因前列腺癌接受雄激素剥夺疗法（ADT）治疗后出现 MG，并且在停止 ADT 后症状得到改善。我们的病例表明，老年男性的 MG 可能是由雄激素作用引起的。
相似文献
1
Two Elderly Men with Myasthenia Gravis during Androgen Deprivation Therapy for Prostate Cancer.两名老年男性在接受前列腺癌去势治疗时出现重症肌无力。
Intern Med. 2023 Aug 15;62(16):2413-2414. doi: 10.2169/internalmedicine.0474-22. Epub 2023 Jan 12.
2
Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.雄激素剥夺疗法治疗前列腺癌后睾酮的恢复情况。
J Sex Med. 2019 Jun;16(6):872-879. doi: 10.1016/j.jsxm.2019.03.273. Epub 2019 May 9.
3
Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy.雄激素剥夺治疗的非转移性前列腺癌年轻和中年男性患者的痴呆和抑郁风险。
Eur Urol Oncol. 2021 Feb;4(1):66-72. doi: 10.1016/j.euo.2019.08.003. Epub 2019 Oct 14.
4
Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.胰岛素样生长因子-1 与接受促性腺激素释放激素类似物进行局部前列腺癌雄激素剥夺治疗的男性黄体生成素产生的调节有关。
Urol Oncol. 2012 Sep;30(5):596-601. doi: 10.1016/j.urolonc.2010.11.001. Epub 2011 Apr 1.
5
Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.前列腺癌男性患者的雄激素剥夺与骨丢失率增加有关。
Prostate Cancer Prostatic Dis. 2002;5(4):304-10. doi: 10.1038/sj.pcan.4500599.
6
Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer.雄激素剥夺疗法与局限性前列腺癌患者类风湿关节炎风险的关系。
Ann Oncol. 2018 Feb 1;29(2):386-391. doi: 10.1093/annonc/mdx744.
7
The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients.长期雄激素剥夺疗法对前列腺癌患者认知功能和社会经济决策的影响。
Psychooncology. 2020 Aug;29(8):1338-1346. doi: 10.1002/pon.5442. Epub 2020 Jul 2.
8
Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer.前列腺癌雄激素剥夺治疗中的免疫抑制环境。
Front Endocrinol (Lausanne). 2022 Nov 24;13:1055826. doi: 10.3389/fendo.2022.1055826. eCollection 2022.
9
Decreased testosterone recovery after androgen deprivation therapy for prostate cancer.雄激素剥夺治疗前列腺癌后睾酮恢复减少。
Can J Urol. 2021 Aug;28(4):10738-10742.
10
Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures-a study from the fractures and fall injuries in the elderly cohort (FRAILCO).患有前列腺癌和雄激素剥夺疗法的患者骨折风险增加-来自老年队列骨折和跌倒伤害研究（FRAILCO）。
Osteoporos Int. 2019 Jan;30(1):115-125. doi: 10.1007/s00198-018-4722-3. Epub 2018 Oct 15.
本文引用的文献
1
Androgen-Induced Immunosuppression.雄激素诱导的免疫抑制。
Front Immunol. 2018 Apr 17;9:794. doi: 10.3389/fimmu.2018.00794. eCollection 2018.
2
Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer.雄激素剥夺疗法与局限性前列腺癌患者类风湿关节炎风险的关系。
Ann Oncol. 2018 Feb 1;29(2):386-391. doi: 10.1093/annonc/mdx744.
3
Androgen deprivation and immunotherapy for the treatment of prostate cancer.雄激素剥夺治疗与免疫治疗联合用于前列腺癌的治疗。
Endocr Relat Cancer. 2017 Dec;24(12):T297-T310. doi: 10.1530/ERC-17-0145. Epub 2017 Aug 16.
4
Low testosterone and myasthenia gravis in males: a national record-linkage study.男性低睾酮水平与重症肌无力：一项全国性记录链接研究。
J Neurol. 2016 Dec;263(12):2547-2548. doi: 10.1007/s00415-016-8319-5. Epub 2016 Oct 24.
5
Sex bias in CNS autoimmune disease mediated by androgen control of autoimmune regulator.由雄激素对自身免疫调节因子的控制介导的中枢神经系统自身免疫性疾病中的性别偏见。
Nat Commun. 2016 Apr 13;7:11350. doi: 10.1038/ncomms11350.
6
A systematic review of population based epidemiological studies in Myasthenia Gravis.一项基于人群的重症肌无力流行病学研究的系统综述。
BMC Neurol. 2010 Jun 18;10:46. doi: 10.1186/1471-2377-10-46.
7
Activation of thymic regeneration in mice and humans following androgen blockade.雄激素阻断后小鼠和人类胸腺再生的激活。
J Immunol. 2005 Aug 15;175(4):2741-53. doi: 10.4049/jimmunol.175.4.2741.
8
Dehydroepiandrosterone therapy ameliorates experimental autoimmune myasthenia gravis in Lewis rats.脱氢表雄酮疗法可改善Lewis大鼠实验性自身免疫性重症肌无力。
J Clin Immunol. 2003 Mar;23(2):100-6. doi: 10.1023/a:1022572727408.
9
Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.重症肌无力：临床研究标准建议。美国重症肌无力基金会医学科学咨询委员会特别工作组
Neurology. 2000 Jul 12;55(1):16-23. doi: 10.1212/wnl.55.1.16.
10
Myasthenia gravis activities of daily living profile.重症肌无力日常生活活动概况
Neurology. 1999 Apr 22;52(7):1487-9. doi: 10.1212/wnl.52.7.1487.
Zotero 插件